Abstract

Background The human skeleton is the most common organ to be affected by metastatic cancer (skeletal or bone metastases). The prevalence of skeletal disease is greatest in breast and prostate carcinoma. Bone metastases lesions weaken bone structure, causing a range of symptoms and complications. Sufferers of breast and prostate cancers may develop Skeletal related events (SRE). These SRE are defined as pain that require palliative radiotherapy or surgery to bone, hypercalcaemia, pathologic fractures, spinal cord compression and bone marrow failure. These complications contribute to a decline in patients’ HRQOL (health related quality of life). However, information on treatment costs of breast and prostate cancers and multidimensional assessments of QOL are limited. Thus this study aim to obtain both cost and QOL of breast and prostate cancers patients and to determine their relationship with the patients sociodemograhic profiles (age, ethnicity, income) and disease profile (tumour types, cancer stages and SRE status).

Highlights

  • The human skeleton is the most common organ to be affected by metastatic cancer

  • The prevalence of skeletal disease is greatest in breast and prostate carcinoma

  • The association of risk factors and cost and QOL will later be determined through statistical analysis

Read more

Summary

Background

The human skeleton is the most common organ to be affected by metastatic cancer (skeletal or bone metastases). Sufferers of breast and prostate cancers may develop Skeletal related events (SRE). These SRE are defined as pain that require palliative radiotherapy or surgery to bone, hypercalcaemia, pathologic fractures, spinal cord compression and bone marrow failure. These complications contribute to a decline in patients’ HRQOL (health related quality of life). This study aim to obtain both cost and QOL of breast and prostate cancers patients and to determine their relationship with the patients sociodemograhic profiles (age, ethnicity, income) and disease profile (tumour types, cancer stages and SRE status)

Objective
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.